Isleworth Healthcare Acquisition Corp.
ISLE
NASDAQ Capital Market10.01
USD
-0.13
- -
CIK
0001837997
ISIN
US46468P1021
Return %
Stock
S&P500
1Y
1.62
26.53
3Y
3.20
76.60
5Y
3.20
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Robert S. Whitehead
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 970 Lake Carillon Drive St. Petersburg FL United States of America 33701
- IPO Date
- Mar 29, 2021
- CIK
- 0001837997
- Website
- isleworthhealthcare.com
- Similar Companies
- Business
- Isleworth Healthcare Acquisition Corp. Isleworth Healthcare Acquisition Corp. is a blank check company whose principal business activity centers on effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations with one or more businesses, with a specific focus on targets in the biopharmaceutical or medical technology and device industries. The company does not have significant operations or generate revenue; instead, it maintains cash in trust for deployment in a qualifying transaction while targeting high-growth healthcare entities with innovative technologies and strong competitive positions, primarily in North America and Europe. Incorporated in 2020 and headquartered at 360 Central Avenue, First Central Tower, Suite 800, St. Petersburg, Florida, Isleworth Healthcare Acquisition Corp. holds approximately $262 million in market capitalization with 26.2 million shares outstanding and substantial institutional ownership of 70.8%. In recent developments, the company terminated its merger agreement with Cytovia Therapeutics, Inc. in June 2022 after an initial announcement in April 2022 valued at $602 million, proceeded to liquidate and redeem shares at around $10.01 per share in August 2022 upon failing to complete a business combination by its deadline, and as of late 2025 continues to trade on Nasdaq without a completed de-SPAC transaction or new strategic alliances.